Today is Tuesday, Oct. 22, 2019

Department of Internal Medicine

Infectious Diseases

Photo of  Carl Fichtenbaum, MD

Carl Fichtenbaum, MD

Associate Chairman of Medicine for Translational Research, Professor of Clinical Medicine

Education/Credentials
  • Bachelor's Degree: University of Missouri
  • Medical Degree: University of Missouri
  • Residency : Bridgeport Hospital
  • Chief Medical Residency : Bridgeport Hospital
  • Fellowship: Yale University School of Medicine
  • Fellowship: Barnes Hospital/Washington University School of Medicine
  • Fellowship: National Institute of Drug Abuse

Board Certifications & Licenses
  • Board Certified Diplomate National Board of Medical Examiners, 1986
  • Board Certified Diplomate American Board of Internal Medicine, 1989
  • Board Certified Diplomate American Board of Pediatrics, 1989
  • Board Certified Diplomate American Board of Internal Medicine, Certification in Infectious Diseases, 1994
Contact Information
  • UC Health Holmes Hospital
  • Room 3114
  • Albert Sabin Way at Eden Avenue
  • Cincinnati, Ohio 45219
  • Office 513-584-6977
  • Fax 513-584-6386
  • Email carl.fichtenbaum@uc.edu

Peer Reviewed Publications

Display All

Cahn, Pedro; Madero, Juan Sierra; Arribas, José Ramón; Antinori, Andrea; Ortiz, Roberto; Clarke, Amanda E; Hung, Chien-Ching; Rockstroh, Jürgen K; Girard, Pierre-Marie; Sievers, Jörg; Man, Choy; Currie, Alexander; Underwood, Mark; Tenorio, Allan R; Pappa, Keith; Wynne, Brian; Fettiplace, Anna; Gartland, Martin; Aboud, Michael; Smith, Kimberly 2018. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet (London, England), ,

Gianella, Sara; Marconi, Vincent C; Berzins, Baiba; Benson, Constance A; Sax, Paul; Fichtenbaum, Carl J; Wilkin, Timothy; Vargas, Millie; Deng, Qianqian; Oliveira, Michelli F; Moser, Carlee; Taiwo, Babafemi O 2018. Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy. Journal of acquired immune deficiency syndromes (1999), 79 5, e112-e114

Hsue, Priscilla Y; Ribaudo, Heather J; Deeks, Steven G; Bell, Tanvir; Ridker, Paul M; Fichtenbaum, Carl; Daar, Eric S; Havlir, Diane; Yeh, Eunice; Tawakol, Ahmed; Lederman, Michael; Currier, Judith S; Stein, James H 2018. Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, ,

Huaman, Moises A; Henson, David; Rondan, Paola L; Ticona, Eduardo; Miranda, Gustavo; Kryscio, Richard J; Mugruza, Raquel; Aranda, Ernesto; Ticona, Cesar; Abarca, Susan; Heredia, Paula; Aguirre, Andres; Sterling, Timothy R; Garvy, Beth A; Fichtenbaum, Carl J 2018. Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru. PloS one, 13 9, e0202191

Huaman, Moises A; Ticona, Eduardo; Miranda, Gustavo; Kryscio, Richard J; Mugruza, Raquel; Aranda, Ernesto; Rondan, Paola L; Henson, David; Ticona, Cesar; Sterling, Timothy R; Fichtenbaum, Carl J; Garvy, Beth A 2018. The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 66 6, 886-892

Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge; Gupta, Samir K; McComsey, Grace A; Klingman, Karin L; Fichtenbaum, Carl J; Brown, Todd T; Taiwo, Babafemi O 2018. Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS (London, England), 32 17, 2517-2524

Orkin, Chloe; Molina, Jean-Michel; Negredo, Eugenia; Arribas, José R; Gathe, Joseph; Eron, Joseph J; Van Landuyt, Erika; Lathouwers, Erkki; Hufkens, Veerle; Petrovic, Romana; Vanveggel, Simon; Opsomer, Magda 2018. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. The lancet. HIV, 5 1, e23-e34

Rai, Mohammad A; Pannek, Sam; Fichtenbaum, Carl J 2018. Emerging reverse transcriptase inhibitors for HIV-1 infection. Expert opinion on emerging drugs, 23 2, 149-157

Shive, Carey L; Judge, Chelsey J; Clagett, Brian; Kalayjian, Robert C; Osborn, Melissa; Sherman, Kenneth E; Fichtenbaum, Carl; Gandhi, Rajesh T; Kang, Minhee; Popkin, Daniel L; Sieg, Scott F; Lederman, Michael M; Rodriguez, Benigno; Anthony, Donald D 2018. Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. Vaccine, 36 4, 453-460

Taiwo, Babafemi O; Marconi, Vincent C; Berzins, Baiba; Moser, Carlee B; Nyaku, Amesika N; Fichtenbaum, Carl J; Benson, Constance A; Wilkin, Timothy; Koletar, Susan L; Colasanti, Jonathan; Acosta, Edward P; Li, Jonathan Z; Sax, Paul E 2018. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 66 11, 1794-1797

Utay, Netanya S; Kitch, Douglas W; Yeh, Eunice; Fichtenbaum, Carl J; Lederman, Michael M; Estes, Jacob D; Deleage, Claire; Magyar, Clara; Nelson, Scott D; Klingman, Karen L; Bastow, Barbara; Luque, Amneris E; McComsey, Grace A; Douek, Daniel C; Currier, Judith S; Lake, Jordan E 2018. Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone. The Journal of infectious diseases, 217 11, 1770-1781

Cahn, Pedro; Kaplan, Richard; Sax, Paul E; Squires, Kathleen; Molina, Jean-Michel; Avihingsanon, Anchalee; Ratanasuwan, Winai; Rojas, Evelyn; Rassool, Mohammed; Bloch, Mark; Vandekerckhove, Linos; Ruane, Peter; Yazdanpanah, Yazdan; Katlama, Christine; Xu, Xia; Rodgers, Anthony; East, Lilly; Wenning, Larissa; Rawlins, Sandy; Homony, Brenda; Sklar, Peter; Nguyen, Bach-Yen; Leavitt, Randi; Teppler, Hedy 2017. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. The lancet. HIV, 4 11, e486-e494

Huaman, M A; Kryscio, R J; Fichtenbaum, C J; Henson, D; Salt, E; Sterling, T R; Garvy, B A 2017. Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis. Epidemiology and infection, 145 7, 1363-1367

Rentz, Michael F; Ruffner, Andrew H; Ancona, Rachel M; Hart, Kimberly W; Kues, John R; Barczak, Christopher M; Lindsell, Christopher J; Fichtenbaum, Carl J; Lyons, Michael S 2017. Pilot Integration of HIV Screening and Healthcare Settings with Multi- Component Social Network and Partner Testing for HIV Detection. Current HIV research, 15 5, 372-381

Chan, Ellen S; Landay, Alan L; Brown, Todd T; Ribaudo, Heather J; Mirmonsef, Paria; Ofotokun, Igho; Weitzmann, M Neale; Martinson, Jeffrey; Klingman, Karin L; Eron, Joseph J; Fichtenbaum, Carl J; Plants, Jill; Taiwo, Babafemi O 2016. Differential CD4+ cell count increase and CD4+?: ?CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS (London, England), 30 13, 2091-7

Jacobson, Jeffrey M; Zheng, Lu; Wilson, Cara C; Tebas, Pablo; Matining, Roy M; Egan, Michael A; Eldridge, John; Landay, Alan L; Clifford, David B; Luetkemeyer, Anne F; Tiu, Jennifer; Martinez, Ana L; Janik, Jennifer; Spitz, Teresa A; Hural, John; McElrath, Juliana; Frahm, Nicole 2016. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. Journal of acquired immune deficiency syndromes (1999), 71 2, 163-71

Lyons, Michael S; Kunnathur, Vidhya A; Rouster, Susan D; Hart, Kimberly W; Sperling, Matthew I; Fichtenbaum, Carl J; Sherman, Kenneth E 2016. Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 62 9, 1066-71

Stellbrink, Hans-Jürgen; Le Fevre, Eric; Carr, Andrew; Saag, Michael S; Mukwaya, Geoffrey; Nozza, Silvia; Valluri, Srinivas Rao; Vourvahis, Manoli; Rinehart, Alex R; McFadyen, Lynn; Fichtenbaum, Carl; Clark, Andrew; Craig, Charles; Fang, Annie F; Heera, Jayvant 2016. Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. AIDS (London, England), 30 8, 1229-38

Dubé, Michael P; Komarow, Lauren; Fichtenbaum, Carl J; Cadden, Joseph J; Overton, Edgar T; Hodis, Howard N; Currier, Judith S; Stein, James H 2015. Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 61 5, 840-9

Longenecker, Chris T; Kitch, Douglas; Sax, Paul E; Daar, Eric S; Tierney, Camlin; Gupta, Samir K; McComsey, Grace A 2015. Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s. Journal of acquired immune deficiency syndromes (1999), 69 2, 168-77

Taiwo, Babafemi O; Chan, Ellen S; Fichtenbaum, Carl J; Ribaudo, Heather; Tsibris, Athe; Klingman, Karin L; Eron, Joseph J; Berzins, Baiba; Robertson, Kevin; Landay, Alan; Ofotokun, Igho; Brown, Todd 2015. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 61 7, 1179-88

Tashima, Karen T; Mollan, Katie R; Na, Lumine; Gandhi, Rajesh T; Klingman, Karin L; Fichtenbaum, Carl J; Andrade, Adriana; Johnson, Victoria A; Eron, Joseph J; Smeaton, Laura; Haubrich, Richard H 2015. Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. HIV clinical trials, 16 4, 147-56

Tashima, Karen T; Smeaton, Laura M; Fichtenbaum, Carl J; Andrade, Adriana; Eron, Joseph J; Gandhi, Rajesh T; Johnson, Victoria A; Klingman, Karin L; Ritz, Justin; Hodder, Sally; Santana, Jorge L; Wilkin, Timothy; Haubrich, Richard H 2015. HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial. Annals of internal medicine, 163 12, 908-17

Lennox, J L; Landovitz, R J; Ribaudo, H J; Ofotokun, I; Na, L H; Godfrey, C; Kuritzkes, D R; Sagar, M; Brown, T T; Cohn, S E; McComsey, G A; Aweeka, F; Fichtenbaum, C J; Presti, R M; Koletar, S L; Haas, D W; Patterson, K B; Benson, C A; Baugh, B P; Leavitt, R Y; Rooney, J F; Seekins, D; Currier, J S 2014. Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. Annals of internal medicine, 161 7, I-22

Lennox, Jeffrey L; Landovitz, Raphael J; Ribaudo, Heather J; Ofotokun, Ighovwerha; Na, Lumine H; Godfrey, Catherine; Kuritzkes, Daniel R; Sagar, Manish; Brown, Todd T; Cohn, Susan E; McComsey, Grace A; Aweeka, Francesca; Fichtenbaum, Carl J; Presti, Rachel M; Koletar, Susan L; Haas, David W; Patterson, Kristine B; Benson, Constance A; Baugh, Bryan P; Leavitt, Randi Y; Rooney, James F; Seekins, Daniel; Currier, Judith S 2014. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Annals of internal medicine, 161 7, 461-71

Moschella, Phillip C; Hart, Kimberly W; Ruffner, Andrew H; Lindsell, Christopher J; Wayne, D Beth; Sperling, Matthew I; Trott, Alexander T; Fichtenbaum, Carl J; Lyons, Michael S 2014. Prevalence of undiagnosed acute and chronic HIV in a lower-prevalence urban emergency department. American journal of public health, 104 9, 1695-9

Sandler, Netanya G; Zhang, Xinyan; Bosch, Ronald J; Funderburg, Nicholas T; Choi, Andrew I; Robinson, Janet K; Fine, Derek M; Coombs, Robert W; Jacobson, Jeffrey M; Landay, Alan L; Douek, Daniel C; Tressler, Randall; Read, Sarah W; Wilson, Cara C; Deeks, Steven G; Lederman, Michael M; Gandhi, Rajesh T 2014. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. The Journal of infectious diseases, 210 10, 1549-54

Warm, Eric J; Mathis, Bradley R; Held, Justin D; Pai, Savita; Tolentino, Jonathan; Ashbrook, Lauren; Lee, Cheryl K; Lee, David; Wood, Sharice; Fichtenbaum, Carl J; Schauer, Daniel; Munyon, Ryan; Mueller, Caroline 2014. Entrustment and Mapping of Observable Practice Activities for Resident Assessment. Journal of general internal medicine, ,

Lyons, Michael S; Lindsell, Christopher J; Ruffner, Andrew H; Wayne, D Beth; Hart, Kimberly W; Sperling, Matthew I; Trott, Alexander T; Fichtenbaum, Carl J 2013. Randomized Comparison of Universal and Targeted HIV Screening in the Emergency Department. Journal of acquired immune deficiency syndromes (1999), ,

McComsey, Grace A; Daar, Eric S; O'Riordan, MaryAnn; Collier, Ann C; Kosmiski, Lisa; Santana, Jorge L; Fichtenbaum, Carl J; Fink, Heidi; Sax, Paul E; Libutti, Daniel E; Gerschenson, Mariana 2013. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. The Journal of infectious diseases, 207 4, 604-11

Wohl, David A; Arnoczy, Gretchen; Fichtenbaum, Carl J; Campbell, Thomas; Taiwo, Babafemi; Hicks, Charles; McComsey, Grace A; Koletar, Susan; Sax, Paul; Tebas, Pablo; Ha, Belinda; Massengale, Kelly; Walsh, Kendall; Stein, James H 2013. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antiviral therapy, ,

Presicce, Pietro; Moreno-Fernandez, Maria E; Rusie, Laura K; Fichtenbaum, Carl; Chougnet, Claire A 2012. In vitro HIV infection impairs the capacity of myeloid dendritic cells to induce regulatory T cells. PloS one, 7 8, e42802

Samineni, Divya; Desai, Pankaj B; Sallans, Larry; Fichtenbaum, Carl J 2012. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. Journal of clinical pharmacology, 52 6, 922-31

Brehm, Jessica H; Lalama, Christina M; Hughes, Michael D; Haubrich, Richard; Riddler, Sharon A; Sluis-Cremer, Nicolas; Mellors, John W 2011. Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase. Journal of acquired immune deficiency syndromes (1999), 56 4, 344-8

Fichtenbaum, Carl J 2011. Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. Current infectious disease reports, 13 1, 94-101

Fichtenbaum, Carl J; Evans, Scott E; Aberg, Judith A 2011. High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. AIDS (London, England), 25 16, 2053

Hudepohl, Nathan J; Lindsell, Christopher J; Hart, Kimberly W; Ruffner, Andrew H; Trott, Alexander T; Fichtenbaum, Carl J; Lyons, Michael S 2011. Effect of an emergency department HIV testing program on the proportion of emergency department patients who have been tested. Annals of emergency medicine, 58 1 Suppl 1, S140-4

Lyons, Michael S; Lindsell, Christopher J; Wayne, D Beth; Ruffner, Andrew H; Hart, Kimberly W; Fichtenbaum, Carl J; Trott, Alexander T; Sullivan, Patrick S 2011. Comparison of missed opportunities for earlier HIV diagnosis in 3 geographically proximate emergency departments. Annals of emergency medicine, 58 1 Suppl 1, S17-22.e1

Nyakeriga, Alice M; Ying, Jun; Shire, Norah J; Fichtenbaum, Carl J; Chougnet, Claire A 2011. Highly active antiretroviral therapy in patients infected with human immunodeficiency virus increases CD40 ligand expression and IL-12 production in cells ex vivo. Viral immunology, 24 4, 281-9

Presicce, Pietro; Orsborn, Kris; King, Eileen; Pratt, Jesse; Fichtenbaum, Carl J; Chougnet, Claire A 2011. Frequency of circulating regulatory T cells increases during chronic HIV infection and is largely controlled by highly active antiretroviral therapy. PloS one, 6 12, e28118

Sax, Paul E; Tierney, Camlin; Collier, Ann C; Daar, Eric S; Mollan, Katie; Budhathoki, Chakra; Godfrey, Catherine; Jahed, Nasreen C; Myers, Laurie; Katzenstein, David; Farajallah, Awny; Rooney, James F; Ha, Belinda; Woodward, William C; Feinberg, Judith; Tashima, Karen; Murphy, Robert L; Fischl, Margaret A 2011. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. The Journal of infectious diseases, 204 8, 1191-201

Sitlinger, Andrea P; Lindsell, Christopher J; Ruffner, Andrew H; Wayne, D Beth; Hart, Kimberly W; Trott, Alexander T; Fichtenbaum, Carl J; Lyons, Michael S 2011. Preliminary program evaluation of emergency department HIV prevention counseling. Annals of emergency medicine, 58 1 Suppl 1, S120-5.e1-3

Taiwo, Babafemi; Zheng, Lu; Gallien, Sebastien; Matining, Roy M; Kuritzkes, Daniel R; Wilson, Cara C; Berzins, Baiba I; Acosta, Edward P; Bastow, Barbara; Kim, Peter S; Eron, Joseph J 2011. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS (London, England), 25 17, 2113-22

Ubhayakar, Nitin D; Lindsell, Christopher J; Raab, Dana L; Ruffner, Andrew H; Trott, Alexander T; Fichtenbaum, Carl J; Lyons, Michael S 2011. Risk, reasons for refusal, and impact of counseling on consent among ED patients declining HIV screening. The American journal of emergency medicine, 29 4, 367-72

Fichtenbaum, Carl J 2010. Does antiretroviral therapy increase or decrease the risk of cardiovascular disease? Current HIV/AIDS reports, 7 2, 92-8

Flexner, Charles; Tierney, Camlin; Gross, Robert; Andrade, Adriana; Lalama, Christina; Eshleman, Susan H; Aberg, Judith; Sanne, Ian; Parsons, Teresa; Kashuba, Angela; Rosenkranz, Susan L; Kmack, Anne; Ferguson, Elaine; Dehlinger, Marjorie; Mildvan, Donna 2010. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50 7, 1041-52

Jacobson, Jeffrey M; Lalezari, Jacob P; Thompson, Melanie A; Fichtenbaum, Carl J; Saag, Michael S; Zingman, Barry S; D'Ambrosio, Paul; Stambler, Nancy; Rotshteyn, Yakov; Marozsan, Andre J; Maddon, Paul J; Morris, Stephen A; Olson, William C 2010. Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-infected Adults. Antimicrobial agents and chemotherapy, ,

McComsey, Grace A; Walker, Ulrich A; Budhathoki, Chakra B; Su, Zhaohui; Currier, Judith S; Kosmiski, Lisa; Naini, Linda G; Charles, Stéphannie; Medvik, Kathy; Aberg, Judith A 2010. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS (London, England), 24 16, 2507-15

Murphy, Robert L; Berzins, Baiba; Zala, Carlos; Fichtenbaum, Carl; Dube, Michael P; Guaraldi, Giovanni; Torriani, Francesca; Belsey, Elizabeth; Mitchell, Carol; Stein, James H 2010. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS (London, England), 24 6, 885-90

Samineni, Divya; Fichtenbaum, Carl J 2010. Fenofibrate in the treatment of dyslipidemia associated with HIV infection. Expert opinion on drug metabolism & toxicology, 6 8, 995-1004

Fichtenbaum, Carl J 2009. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Current infectious disease reports, 11 1, 84-92

Gross, Robert; Tierney, Camlin; Andrade, Adriana; Lalama, Christina; Rosenkranz, Susan; Eshleman, Susan H; Flanigan, Timothy; Santana, Jorge; Salomon, Nadim; Reisler, Ronald; Wiggins, Ilene; Hogg, Evelyn; Flexner, Charles; Mildvan, Donna 2009. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Archives of internal medicine, 169 13, 1224-32

Haubrich, Richard H; Riddler, Sharon A; DiRienzo, A Gregory; Komarow, Lauren; Powderly, William G; Klingman, Karin; Garren, Kevin W; Butcher, David L; Rooney, James F; Haas, David W; Mellors, John W; Havlir, Diane V 2009. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (London, England), 23 9, 1109-18

Lyons, Michael S; Lindsell, Christopher J; Raab, Dana L; Ruffner, Andrew H; Trott, Alexander T; Fichtenbaum, Carl J 2009. Comparison of emergency department HIV testing data with visit or patient as the unit of analysis. Journal of medical screening, 16 1, 29-32

Lyons, Michael S; Lindsell, Christopher J; Ruffner, Andrew H; Trott, Alexander T; Fichtenbaum, Carl J 2009. Relationship of self-reported prior testing history to undiagnosed HIV positivity and HIV risk. Current HIV research, 7 6, 580-8

Nyakeriga, Alice M; Fichtenbaum, Carl J; Goebel, Jens; Nicolaou, Stella A; Conforti, Laura; Chougnet, Claire A 2009. Engagement of the CD4 receptor affects the redistribution of Lck to the immunological synapse in primary T cells: implications for T-cell activation during human immunodeficiency virus type 1 infection. Journal of virology, 83 3, 1193-200

Dubé, Michael P; Lipshultz, Steven E; Fichtenbaum, Carl J; Greenberg, Richard; Schecter, Alison D; Fisher, Stacy D 2008. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation, 118 2, e36-40

Fichtenbaum, Carl J 2008. Editorial comment: the head bone is connected to the body bone. The AIDS reader, 18 5, 265

Gerber, John G; Kitch, Douglas W; Fichtenbaum, Carl J; Zackin, Robert A; Charles, Stéphannie; Hogg, Evelyn; Acosta, Edward P; Connick, Elizabeth; Wohl, David; Kojic, E Milu; Benson, Constance A; Aberg, Judith A 2008. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. Journal of acquired immune deficiency syndromes (1999), 47 4, 459-66

Jacobson, Jeffrey M; Saag, Michael S; Thompson, Melanie A; Fischl, Margaret A; Liporace, Ralph; Reichman, Richard C; Redfield, Robert R; Fichtenbaum, Carl J; Zingman, Barry S; Patel, Mahesh C; Murga, Jose D; Pemrick, Suzanne M; D'Ambrosio, Paul; Michael, Marti; Kroger, Hans; Ly, Hieu; Rotshteyn, Yakov; Buice, Robert; Morris, Stephen A; Stavola, Joseph J; Maddon, Paul J; Kremer, Alton B; Olson, William C 2008. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. The Journal of infectious diseases, 198 9, 1345-52

Lyons, Michael S; Lindsell, Christopher J; R N, Deanna A Hawkins; Rn, Dana L Raab; Trott, Alexander T; Fichtenbaum, Carl J 2008. Contributions to early HIV diagnosis among patients linked to care vary by testing venue. BMC public health, 8 , 220

Riddler, Sharon A; Haubrich, Richard; DiRienzo, A Gregory; Peeples, Lynne; Powderly, William G; Klingman, Karin L; Garren, Kevin W; George, Tania; Rooney, James F; Brizz, Barbara; Lalloo, Umesh G; Murphy, Robert L; Swindells, Susan; Havlir, Diane; Mellors, John W 2008. Class-sparing regimens for initial treatment of HIV-1 infection. The New England journal of medicine, 358 20, 2095-106

Stein, James H; Komarow, Lauren; Cotter, Bruno R; Currier, Judith S; Dubé, Michael P; Fichtenbaum, Carl J; Gerschenson, Mariana; Mitchell, Carol K C; Murphy, Robert L; Squires, Kathleen; Parker, Robert A; Torriani, Francesca J 2008. Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy. Journal of clinical lipidology, 2 6, 464-471

Torriani, Francesca J; Komarow, Lauren; Parker, Robert A; Cotter, Bruno R; Currier, Judith S; Dubé, Michael P; Fichtenbaum, Carl J; Gerschenson, Mariana; Mitchell, Carol K C; Murphy, Robert L; Squires, Kathleen; Stein, James H 2008. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. Journal of the American College of Cardiology, 52 7, 569-76

Vazquez, José A; Schranz, Jennifer A; Clark, Kay; Goldstein, Beth P; Reboli, Annette; Fichtenbaum, Carl 2008. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. Journal of acquired immune deficiency syndromes (1999), 48 3, 304-9

Velilla, P A; Shata, M T; Lages, C S; Ying, J; Fichtenbaum, C J; Chougnet, C 2008. Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients. AIDS research and human retroviruses, 24 1, 52-61

de Perio, Marie A; Gomez, Francisco J; Frame, Peter T; Fichtenbaum, Carl J 2007. A truvada hypersensitivity reaction simulating abacavir hypersensitivity. AIDS (London, England), 21 16, 2252-3

Huang, I; Leach, J L; Fichtenbaum, C J; Narayan, R K 2007. Osteomyelitis of the skull in early-acquired syphilis: evaluation by MR imaging and CT. AJNR. American journal of neuroradiology, 28 2, 307-8

Lyons, Michael S; Raab, Dana L; Lindsell, Christopher J; Trott, Alexander T; Fichtenbaum, Carl J 2007. A novel emergency department based prevention intervention program for people living with HIV: evaluation of early experiences. BMC health services research, 7 , 164

Shire, Norah J; Rouster, Susan D; Stanford, Sandra D; Blackard, Jason T; Martin, Christina M; Fichtenbaum, Carl J; Sherman, Kenneth E 2007. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. Journal of acquired immune deficiency syndromes (1999), 44 3, 309-14

Aberg, Judith A; Rosenkranz, Susan L; Fichtenbaum, Carl J; Alston, Beverly L; Brobst, Susan W; Segal, Yoninah; Gerber, John G 2006. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS (London, England), 20 5, 725-9

Robertson, Jaime; Meier, Matthew; Wall, Jennifer; Ying, Jun; Fichtenbaum, Carl J 2006. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 42 11, 1639-46

Wohl, D A; McComsey, G; Tebas, P; Brown, T T; Glesby, M J; Reeds, D; Shikuma, C; Mulligan, K; Dube, M; Wininger, D; Huang, J; Revuelta, M; Currier, J; Swindells, S; Fichtenbaum, C; Basar, M; Tungsiripat, M; Meyer, W; Weihe, J; Wanke, C 2006. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 43 5, 645-53

Aberg, Judith A; Zackin, Robert A; Brobst, Susan W; Evans, Scott R; Alston, Beverly L; Henry, W Keith; Glesby, Marshall J; Torriani, Francesca J; Yang, Yijun; Owens, Susan I; Fichtenbaum, Carl J 2005. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS research and human retroviruses, 21 9, 757-67

Fichtenbaum, Carl J; Hadigan, Colleen M; Kotler, Donald P; Pierone, Gerald; Sax, Paul E; Steinhart, Corklin R; Tebas, Pablo 2005. Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care. IAPAC monthly, 11 2, 38-46

Gerber, John G; Rosenkranz, Susan L; Fichtenbaum, Carl J; Vega, Jose M; Yang, Amy; Alston, Beverly L; Brobst, Susan W; Segal, Yoninah; Aberg, Judith A 2005. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. Journal of acquired immune deficiency syndromes (1999), 39 3, 307-12

Glesby, Marshall J; Aberg, Judith A; Kendall, Michelle A; Fichtenbaum, Carl J; Hafner, Richard; Hall, Stephen; Grosskopf, Nicole; Zolopa, Andrew R; Gerber, John G 2005. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clinical pharmacology and therapeutics, 78 2, 143-53

Glesby, Marshall J; Bassett, Roland; Alston-Smith, Beverly; Fichtenbaum, Carl; Jacobson, Elizabeth L; Brass, Clifford; Owens, Susan; Sulkowski, Mark; Race, Elizabeth M; Sherman, Kenneth E 2005. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection. The Journal of infectious diseases, 191 5, 686-93

Goldman, Mitchell; Cloud, Gretchen A; Wade, Karen D; Reboli, Annette C; Fichtenbaum, Carl J; Hafner, Richard; Sobel, Jack D; Powderly, William G; Patterson, Thomas F; Wheat, Lawrence J; Stein, David K; Dismukes, William E; Filler, Scott G 2005. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 41 10, 1473-80

Acosta, Edward P; Wu, Hulin; Hammer, Scott M; Yu, Song; Kuritzkes, Daniel R; Walawander, Ann; Eron, Joseph J; Fichtenbaum, Carl J; Pettinelli, Carla; Neath, Denise; Ferguson, Elaine; Saah, Alfred J; Gerber, John G 2004. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. Journal of acquired immune deficiency syndromes (1999), 37 3, 1358-66

Goldman, Mitchell; Zackin, Robert; Fichtenbaum, Carl J; Skiest, Daniel J; Koletar, Susan L; Hafner, Richard; Wheat, L Joseph; Nyangweso, Peter M; Yiannoutsos, Constantin T; Schnizlein-Bick, Carol T; Owens, Susan; Aberg, Judith A 2004. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 38 10, 1485-9

Zhang, Rui; Fichtenbaum, Carl J; Hildeman, David A; Lifson, Jeffrey D; Chougnet, Claire 2004. CD40 ligand dysregulation in HIV infection: HIV glycoprotein 120 inhibits signaling cascades upstream of CD40 ligand transcription. Journal of immunology (Baltimore, Md. : 1950), 172 4, 2678-86

Dubé, Michael P; Stein, James H; Aberg, Judith A; Fichtenbaum, Carl J; Gerber, John G; Tashima, Karen T; Henry, W Keith; Currier, Judith S; Sprecher, Dennis; Glesby, Marshall J 2003. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 37 5, 613-27

Fichtenbaum, Carl J 2003. Antiretrovirals and cardiovascular disease: is HAART bad for your heart? AIDS clinical care, 15 8, 69-73, 76

Landon, Bruce E; Wilson, Ira B; Cohn, Susan E; Fichtenbaum, Carl J; Wong, Mitchell D; Wenger, Neil S; Bozzette, Samuel A; Shapiro, Martin F; Cleary, Paul D 2003. Physician specialization and antiretroviral therapy for HIV. Journal of general internal medicine, 18 4, 233-41

Riddle, Tara M; Fichtenbaum, Carl J; Hui, David Y 2003. Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice. Journal of acquired immune deficiency syndromes (1999), 33 5, 564-70

Daly, Kieran R; Fichtenbaum, Carl J; Tanaka, Reiko; Linke, Michael J; O'Bert, Robert; Thullen, Timothy D; Hui, Michele S; Smulian, Alan G; Walzer, Peter D 2002. Serologic responses to epitopes of the major surface glycoprotein of Pneumocystis jiroveci differ in human immunodeficiency virus-infected and uninfected persons. The Journal of infectious diseases, 186 5, 644-51

David, Max H; Hornung, Richard; Fichtenbaum, Carl J 2002. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 34 1, 98-102

Fichtenbaum, Carl J; Gerber, John G 2002. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clinical pharmacokinetics, 41 14, 1195-211

Fichtenbaum, Carl J; Gerber, John G; Rosenkranz, Susan L; Segal, Yoninah; Aberg, Judith A; Blaschke, Terrence; Alston, Beverly; Fang, Fang; Kosel, Bradley; Aweeka, Francesca 2002. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS (London, England), 16 4, 569-77

Landon, Bruce E; Wilson, Ira B; Wenger, Neil S; Cohn, Susan E; Fichtenbaum, Carl J; Bozzette, Samuel A; Shapiro, Martin F; Cleary, Paul D 2002. Specialty training and specialization among physicians who treat HIV/AIDS in the United States. Journal of general internal medicine, 17 1, 12-22

Levine, Nicholas B; Kurokawa, Ryu; Fichtenbaum, Carl J; Howington, John A; Kuntz, Charles 2002. An immunocompetent patient with primary Scedosporium apiospermum vertebral osteomyelitis. Journal of spinal disorders & techniques, 15 5, 425-30

Riddle, Tara M; Schildmeyer, Nicholas M; Phan, Cam; Fichtenbaum, Carl J; Hui, David Y 2002. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. Journal of lipid research, 43 9, 1458-63

Currier, J S; Williams, P; Feinberg, J; Becker, S; Owens, S; Fichtenbaum, C; Benson, C 2001. Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 32 11, 1615-22

Fichtenbaum, C J 2001. The evaluation and management of dyslipidemia in HIV-infected patients. AIDS clinical care, 13 12, 113-7, 120

Fichtenbaum, C J; Zackin, R; Feinberg, J 2001. Reply to 'Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis' by Holmberg and Moorman. AIDS (London, England), 15 13, 1745

Riddle, T M; Kuhel, D G; Woollett, L A; Fichtenbaum, C J; Hui, D Y 2001. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. The Journal of biological chemistry, 276 40, 37514-9

Riddle, T M; Kuhel, D G; Woollett, L A; Fichtenbaum, C J; Hui, D Y 2001. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. The Journal of biological chemistry, 276 40, 37514-9

Soloway, B; Fichtenbaum, C J 2001. One size does not fit all. AIDS clinical care, 13 10, 92-3

Tantisiriwat, W; Tebas, P; Polish, L B; Casabar, E; Powderly, W G; Fichtenbaum, C J 2001. Elevated lactate levels in hospitalized persons with HIV infection. AIDS research and human retroviruses, 17 3, 195-201

Fichtenbaum, C J; Koletar, S; Yiannoutsos, C; Holland, F; Pottage, J; Cohn, S E; Walawander, A; Frame, P; Feinberg, J; Saag, M; Van der Horst, C; Powderly, W G 2000. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 30 5, 749-56

Fichtenbaum, C J; Zackin, R; Feinberg, J; Benson, C; Griffiths, J K 2000. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS (London, England), 14 18, 2889-93

Fichtenbaum, C J; Zackin, R; Rajicic, N; Powderly, W G; Wheat, L J; Zingman, B S 2000. Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295. AIDS (London, England), 14 7, 845-52

Taylor, B N; Fichtenbaum, C; Saavedra, M; Slavinsky III, J; Swoboda, R; Wozniak, K; Arribas, A; Powderly, W; Fidel Jr, P L 2000. In vivo virulence of Candida albicans isolates causing mucosal infections in people infected with the human immunodeficiency virus. The Journal of infectious diseases, 182 3, 955-9

Fichtenbaum, C J; German, M; Dunagan, W C; Fraser, V J; Medoff, G; Diego, J; Powderly, W G 1999. A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 29 6, 1551-6

Tantisiriwat, W; Tebas, P; Clifford, D B; Powderly, W G; Fichtenbaum, C J 1999. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 28 5, 1152-4

Cottler, L B; Compton, W M; Ben Abdallah, A; Cunningham-Williams, R; Abram, F; Fichtenbaum, C; Dotson, W 1998. Peer-delivered interventions reduce HIV risk behaviors among out-of-treatment drug abusers. Public health reports (Washington, D.C. : 1974), 113 Suppl 1 , 31-41

Fichtenbaum, C J 1998. I hear you knockin' (but you can't come in): potent new HIV therapies are shutting out opportunistic infections. Research initiative, treatment action : RITA, 4 4, 3-7

Fichtenbaum, C J; Powderly, W G 1998. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 26 3, 556-65

Seydel, K B; Zhang, T; Champion, G A; Fichtenbaum, C; Swanson, P E; Tzipori, S; Griffiths, J K; Stanley, S L 1998. Cryptosporidium parvum infection of human intestinal xenografts in SCID mice induces production of human tumor necrosis factor alpha and interleukin-8. Infection and immunity, 66 5, 2379-82

Widmer, G; Tzipori, S; Fichtenbaum, C J; Griffiths, J K 1998. Genotypic and phenotypic characterization of Cryptosporidium parvum isolates from people with AIDS. The Journal of infectious diseases, 178 3, 834-40

Wu, A W; Jacobson, D L; Berzon, R A; Revicki, D A; van der Horst, C; Fichtenbaum, C J; Saag, M S; Lynn, L; Hardy, D; Feinberg, J 1997. The effect of mode of administration on medical outcomes study health ratings and EuroQol scores in AIDS. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 6 1, 3-10

Arribas, J R; Clifford, D B; Fichtenbaum, C J; Commins, D L; Powderly, W G; Storch, G A 1995. Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. The Journal of infectious diseases, 172 2, 527-31

Arribas, J R; Clifford, D B; Fichtenbaum, C J; Roberts, R L; Powderly, W G; Storch, G A 1995. Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. Journal of clinical microbiology, 33 6, 1580-3

Fichtenbaum, C J; Clifford, D B; Powderly, W G 1995. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 10 2, 169-74

Fichtenbaum, C J; Dunagan, W C; Powderly, W G 1995. Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 8 1, 51-7

Fichtenbaum, C J; Woeltje, K F; Powderly, W G 1994. Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 19 3, 417-22

Fichtenbaum, C J; Peterson, L R; Weil, G J 1993. Ehrlichiosis presenting as a life-threatening illness with features of the toxic shock syndrome. The American journal of medicine, 95 4, 351-7

Fichtenbaum, C J; Ritchie, D J; Powderly, W G 1993. Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 16 2, 298-300

Fichtenbaum, C J; Smith, M J 1992. Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 14 1, 353-4

Afridi, S A; Fichtenbaum, C J; Taubin, H 1991. Review of duodenal diverticula. The American journal of gastroenterology, 86 8, 935-8

Fichtenbaum, C J; Kleinman, G M; Haddad, R G 1990. Eosinophilic granuloma of the lung presenting as a solitary pulmonary nodule. Thorax, 45 11, 905-6

Fichtenbaum, C J; Babb, J D; Baker, D A 1988. Erythromycin induced cardiovascular toxicity. Connecticut medicine, 52 3, 135-6

Asmuth, David M; Hinkle, John E; LaMarca, Anthony; Fichtenbaum, Carl J; Somsouk, Ma; Utay, Netanya S; Shaw, Audrey L; Petschow, Bryon W; Detzel, Christopher J; Weaver, Eric M . Evaluation of oral serum-derived bovine immunoglobulins in HIV-infected patients with chronic idiopathic diarrhea. HIV clinical trials, 18 5-6, 205-213

Evans, Scott R; Fichtenbaum, Carl J; Aberg, Judith A . Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087. HIV clinical trials, 8 1, 45-52

Fichtenbaum, Carl J . Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons. HIV clinical trials, 5 6, 416-33

Fichtenbaum, Carl J; Yeh, Tzu-Min; Evans, Scott R; Aberg, Judith A . Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. Journal of clinical lipidology, 4 4, 279-87

Grandominico, Jodi M; Fichtenbaum, Carl J . Short-term effect of HAART on blood pressure in HIV-infected individuals. HIV clinical trials, 9 1, 52-60

Huaman, Moises A; Deepe, George S; Fichtenbaum, Carl J . Elevated Circulating Concentrations of Interferon-Gamma in Latent Tuberculosis Infection. Pathogens & immunity, 1 2, 291-303

Lyons, Michael S; Lindsell, Christopher J; Fichtenbaum, Carl J; Camargo, Carlos A . Interpreting and implementing the 2006 CDC recommendations for HIV testing in health-care settings. Public health reports (Washington, D.C. : 1974), 122 5, 579-83

Mohajer, Mayar Al; Lyons, Michael; King, Eileen; Pratt, Jesse; Fichtenbaum, Carl J . Internal Medicine and Emergency Medicine Physicians Lack Accurate Knowledge of Current CDC HIV Testing Recommendations and Infrequently Offer HIV Testing. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 11 2, 101-8

Monteferrante, M L; Shimkin, P M; Fichtenbaum, C; Kleinman, G M; Lipow, K I . Tentorial traversal by ependymoblastoma. AJNR. American journal of neuroradiology, 12 1, 181

Perazzo, Joseph D; Webel, Allison R; Fichtenbaum, Carl J; McComsey, Grace A . Bone Health in People Living With HIV: The Role of Exercise and Directions for Future Research. The Journal of the Association of Nurses in AIDS Care : JANAC, 29 2, 330-337